A small study of people with Parkinson’s disease found lower levels of inflammation-related markers in their blood after two psilocybin sessions. The findings, published in JAMA Psychiatry and reported on October 21, 2026, offer an early signal for research—not evidence that psilocybin treats Parkinson’s or other inflammatory conditions.
Researchers at the University of California, San Francisco, analyzed blood samples from 12 participants in a pilot study of the feasibility and safety of giving psilocybin to people with Parkinson’s disease. They measured five signaling molecules involved in inflammation before and after the sessions. Inflammation-related levels were significantly lower than at baseline, and the changes persisted one month after the final dose.
A blood marker of mitochondrial stress also improved immediately after psilocybin was given, but that improvement did not persist at the longer-term follow-up. Mitochondria are structures within cells that produce energy; both mitochondrial dysfunction and dysregulated inflammation are features of Parkinson’s disease.
The study had no control group, and participants knew they were receiving psilocybin. Those limits mean the blood-marker changes need to be confirmed in further studies before researchers can determine what caused them or whether they translate into clinical benefits. UCSF researcher Dr. Ellen Bradley described the results as an initial biological signal to investigate. Co-author Aoife O’Donovan likewise cautioned against definitive claims, while noting that the measured markers changed over time.
Earlier laboratory and animal research has suggested that some psychedelics may affect inflammation. Charles Nichols of LSU Health Sciences Center, who was not involved in the new study, said the human findings are encouraging but that only limited conclusions can be drawn from them. Whether such effects could benefit people with Parkinson’s disease—or other conditions—remains an open question.